Aisling Capital Management LP

2. Key Holdings

The portfolio is dominated by a single "core" holding that dictates the overall performance of the fund.

• BridgeBio Pharma Inc. (BBIO): This is the standout position, valued at $316.29 million and comprising 84.29% of the total portfolio. Aisling holds 6.09 million shares. This level of concentration (exceeding 80%) suggests that the firm views BBIO as a mispriced asset with significant upside potential or a platform company central to their investment thesis. The firm increased this stake by 0.3% (adding $54.27 million), signaling continued confidence despite the already massive exposure.
• Syndax Pharmaceuticals (SNDX): The second-largest holding, valued at $20.27 million, represents 5.40% of the portfolio. With 1.32 million shares, this serves as the primary "satellite" position outside of the main BBIO holding.
• Nuvation Bio Inc. (NUVB): The third position accounts for 2.92% of the portfolio ($10.95 million). Notably, this was one of the few positions increased during the quarter, growing by 16.5% ($6.00 million added).